Skip to menu Skip to content Skip to footer
Associate Professor Simone M Goldinger
Associate Professor

Simone M Goldinger

Email: 

Overview

Background

A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.

Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Medicine, University of Zurich
  • Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
  • Doctoral (Research), University of Zurich
  • Professional Doctorate, University of Zurich
  • Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists

Research impacts

Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.

Works

Search Professor Simone M Goldinger’s works on UQ eSpace

137 works between 2006 and 2026

61 - 80 of 137 works

2016

Conference Publication

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?

Haueis, S., Kranzlin, P., Cheng, P., Mangana, J., Dummer, R. and Goldinger, S. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. HOBOKEN: WILEY-BLACKWELL.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?

2016

Journal Article

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects

Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R. and Goldinger, S. M. (2016). MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. European Journal of Cancer, 65, 130-138. doi: 10.1016/j.ejca.2016.06.018

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects

2016

Journal Article

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy

Goldinger, Simone M., Stieger, Pascale, Meier, Barbara, Micaletto, Sara, Contassot, Emmanuel, French, Lars E. and Dummer, Reinhard (2016). Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clinical Cancer Research, 22 (16), 4023-4029. doi: 10.1158/1078-0432.CCR-15-2872

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy

2016

Conference Publication

The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab

Urosevic-Maiwald, M., Goldinger, S. M., Sommerauer, M., Dummer, R. and Schaefer, N. G. (2016). The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab

2016

Conference Publication

Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, J., Amann, V. C., Goldinger, S. M., Kaufmann, C., Frauchiger, A. L., Cheng, P., Stoegner, V., Held, U., Von Moos, R., Romano, E., Michielin, O., Braun, R., Levesque, M. P. and Dummer, R. (2016). Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

2016

Conference Publication

An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel

Thurneysen, S., Cheng, P. F., Nagel, H. W., Kunz, M., Jaberg-Bentele, N., Naegeli, M., Guenova-Hotzenecker, E., Goldinger, S., Mangana, J., Levesque, M. P. and Dummer, R. (2016). An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel

2016

Conference Publication

Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study

Schadendorf, D., Michielin, O., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H. A., Pedroncelli, A. M., Micaletto, S. and Dummer, R. (2016). Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study

2016

Conference Publication

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?

Haueis, S., Kranzlin, P., Cheng, P. F., Mangana, J., Dummer, R. and Goldinger, S. M. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?

2016

Journal Article

Efficacy and Safety of AP0866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial

Goldinger, Simone M., Bischof, Sharon Gobbi, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine and Dummer, Reinhard (2016). Efficacy and Safety of AP0866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. Jama Dermatology, 152 (7), 837-839. doi: 10.1001/jamadermatol.2016.0401

Efficacy and Safety of AP0866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial

2016

Journal Article

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Hofmann, Lars, Forschner, Andrea, Loquai, Carmen, Goldinger, Simone M., Zimmer, Lisa, Ugurel, Selma, Schmidgen, Maria I., Gutzmer, Ralf, Utikal, Jochen S., Goeppner, Daniela, Hassel, Jessica C., Meier, Friedegund, Tietze, Julia K., Thomas, Ioannis, Weishaupt, Carsten, Leverkus, Martin, Wahl, Renate, Dietrich, Ursula, Garbe, Claus, Kirchberger, Michael C., Eigentler, Thomas, Berking, Carola, Gesierich, Anja, Krackhardt, Angela M., Schadendorf, Dirk, Schuler, Gerold, Dummer, Reinhard and Heinzerling, Lucie M. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190-209. doi: 10.1016/j.ejca.2016.02.025

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

2016

Journal Article

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Zimmer, Lisa, Goldinger, Simone M., Hofmann, Lars, Loquai, Carmen, Ugurel, Selma, Thomas, Ioannis, Schmidgen, Maria I., Gutzmer, Ralf, Utikal, Jochen S., Goeppner, Daniela, Hassel, Jessica C., Meier, Friedegund, Tietze, Julia K., Forschner, Andrea, Weishaupt, Carsten, Leverkus, Martin, Wahl, Renate, Dietrich, Ursula, Garbe, Claus, Kirchberger, Michael C., Eigentler, Thomas, Berking, Carola, Gesierich, Anja, Krackhardt, Angela M., Schadendorf, Dirk, Schuler, Gerold, Dummer, Reinhard and Heinzerling, Lucie M. (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 210-225. doi: 10.1016/j.ejca.2016.02.024

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

2016

Journal Article

Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation

Henning, Benjamin, Stieger, Pascale, Kamarachev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2016). Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Research, 26 (3), 304-307. doi: 10.1097/CMR.0000000000000248

Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation

2016

Conference Publication

The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma

Goldinger, Simone M., Courtier, Anais, Jaberg-Bentele, Nicoletta F., Schindler, Sabrina, Manuel, Manuarii, Plantier, Nadia, Treillard, Bertrand, Noel, Marlene, Thi Dan Linh Nguyen-Kim, , Raaijmakers, Marieke Ineke Geertje, Kvistborg, Pia, Haanen, John B. A. G., Dummer, Reinhard and Levesque, Mitchell (2016). The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.3026

The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma

2016

Conference Publication

Derivation and validation of a prediction scale for response to PD-1 monotherapy

Nosrati, Adi, Goldinger, Simone M., Tsai, Katy K., Loo, Kimberly, Tumeh, Paul, Hamid, Omid, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Derivation and validation of a prediction scale for response to PD-1 monotherapy. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9514

Derivation and validation of a prediction scale for response to PD-1 monotherapy

2016

Conference Publication

Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma

Goldinger, Simone M., Tsai, Katy K., Tumeh, Paul, Hamid, Omid, Nosrati, Adi, Loo, Kimberly, Grimes, Barbara, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9549

Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma

2016

Journal Article

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status

Frauchiger, A. L., Mangana, J., Rechsteiner, M., Moch, H., Seifert, B., Braun, R. P., Dummer, R. and Goldinger, S. M. (2016). Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174 (4), 823-830. doi: 10.1111/bjd.14347

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status

2016

Conference Publication

A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitors

Cosgarea, I., Franklin, C., Schwamborn, M., Sucker, A., Griewank, K. G., Weide, B., Loquai, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Gutzmer, R., Goldinger, S. M., Paschen, A., Schadendorf, D. and Schilling, B. (2016). A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitors. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL.

A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitors

2016

Journal Article

Treatment of melanoma brain metastases

Goldinger, Simone M., Panje, Cedric and Nathan, Paul (2016). Treatment of melanoma brain metastases. Current Opinion in Oncology, 28 (2), 159-165. doi: 10.1097/CCO.0000000000000270

Treatment of melanoma brain metastases

2016

Journal Article

Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study

Kunz, M., Urosevic-Maiwald, M., Goldinger, S. M., Frauchiger, A. L., Dreier, J., Belloni, B., Mangana, J., Jenni, D., Dippel, M., Cozzio, A., Guenova, E., Kamarachev, J., French, L. E. and Dummer, R. (2016). Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study. Journal of the European Academy of Dermatology and Venereology, 30 (2), 293-298. doi: 10.1111/jdv.13444

Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study

2016

Journal Article

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patients (vol 42, pg 3049, 2012)

Goldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2016). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients (vol 42, pg 3049, 2012). European Journal of Immunology, 46 (2), 493-493. doi: 10.1002/eji.201670027

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patients (vol 42, pg 3049, 2012)

Supervision

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au